Although the upregulation of PD-L1 can be observed in experimental mouse tumor models after exposure to hypofractionated RT, the combination of PD-L1 blockade therapy and RT may overcome tumor immunosuppression and improve the systemic effects of RT [20]; as a result, the addition of ICI before resistance to RT in TNBC patients could enhance treatment effectiveness. Here, CD274 is linked to neoplasm.